Navigation Links
Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
Date:9/17/2009

ms. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1 is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention. REG2, Regado's second product candidate, consists of a subcutaneously administered formulation of RB006 paired with the IV bolus formulation of RB007. REG2 is intended for use in venous thrombosis indications

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind
'/>"/>

SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
2. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
3. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
4. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
5. Regado Biosciences Expands Medical Advisory Board
6. Regado Biosciences Establishes Medical Advisory Board
7. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
8. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
9. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
10. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
11. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... /CNW/ - Softchoice, a leading North American IT solutions and managed ... of two Cisco® Partner Summit Country awards. ... Security Partner of the Year for Canada ... in Montreal . "We ... awards at this year,s conference," said David MacDonald , ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... 2015   Tamir Biotechnology , a leading developer ... its Ebola antiviral therapy program. Clinical ... currently being evaluated and considered by a number of ... During the first quarter of 2015, the company participated ... The Evaluation of Potential Treatments and Vaccines For Ebola ...
(Date:4/30/2015)... -- Oxford Finance LLC ("Oxford"), a specialty finance firm ... services companies, today announced the closing of a $10 ... a diagnostic testing company focused on improving the accuracy ... improved outcomes.  Proceeds of the loan will be used ... its products in the U.S. and China ...
Breaking Biology Technology:Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Oxford Finance Provides $10 Million Debt Financing to Celula 2
... at American Society of Clinical Oncology , , ... presented data demonstrating the use of ChemoFX(R), a chemosensitivity ... the colorectal cancer cells of individual patients. Results ... colorectal cultures tested, eight percent were responsive to cetuximab, ...
... KVISTGAARD, Denmark, June 1 Detailed ... Saturday at the,ASCO Annual Meeting in Orlando. The presentation was ... School , and the Dana-Farber Cancer,Institute who is also the ... The more detailed analysis supports the headline data that were ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ... intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung ... Clinical Oncology (ASCO) annual meeting. The meeting is being held ... , The presentation, entitled "A Phase II Study of Intravenous ...
Cached Biology Technology:Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 2PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting 3
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... today in Science , researchers from Cambridge, Glasgow ... in how transcription factors, the proteins that bind to ... function over large evolutionary distances. The text books ... they regulate by binding to short, sequence-specific lengths of ...
... reef ecosystems are highly valued for their diverse ... reef fishing and tourism industries, but they are ... over-exploitation. The National Institute for Mathematical ... for its Investigative Workshop, Modeling Reef Ecosystems, to ...
... info@engconfintl.org ) and the Cell Culture Engineering ... proud to announce Prof. Michael J. Betenbaugh, ... Culture Engineering Award.,Mike Betenbaugh ( http://www.jhu.edu/chembe/faculty-template/MichaelBetenbaugh.html ) ... at Johns Hopkins University, Baltimore, MD, USA. ...
Cached Biology News:Rewiring of gene regulation across 300 million years of evolution 2Michael Betenbaugh wins 2010 Cell Culture Engineering award 2
Cytofix Buffer 100 mls...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Rabbit polyclonal to 3-Ethynylestradiol ( Abpromise for all tested applications). Antigen: Ethynylestradiol conjugated to BSA....
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
Biology Products: